NCT05805644

Brief Summary

This study aims to determine the clinical outcomes of stroke patients who are provided with adjunctive robot-mediated task specific therapy(RMTT) and robot-mediated impairment training (RMIT) as compared to those who are provided with adjunctive RMIT.

Trial Health

35
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
96

participants targeted

Target at P50-P75 for not_applicable

Timeline
Completed

Started Jun 2023

Typical duration for not_applicable

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

March 28, 2023

Completed
13 days until next milestone

First Posted

Study publicly available on registry

April 10, 2023

Completed
2 months until next milestone

Study Start

First participant enrolled

June 1, 2023

Completed
2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

May 31, 2025

Completed
7 months until next milestone

Study Completion

Last participant's last visit for all outcomes

December 31, 2025

Completed
Last Updated

April 10, 2023

Status Verified

March 1, 2023

Enrollment Period

2 years

First QC Date

March 28, 2023

Last Update Submit

March 28, 2023

Conditions

Outcome Measures

Primary Outcomes (1)

  • Change of FMA-UE(Fugl Meyer Assessment for Upper Extremity) from baseline

    30 items assessing motor function and 3 items assessing reflex function (0-66, higher scores indicates better outcomes)

    baseline, 1 month and 3 months post commencement of intervention

Secondary Outcomes (10)

  • Change of FMA-UA( Fugl Meyer Assessment-Upper Arm) from baseline

    baseline, 1 month and 3 months post commencement of intervention

  • Change of FMA-W/H (Fugl Meyer Assessment- Wrist/Hand) from baseline

    baseline, 1 month and 3 months post commencement of intervention

  • Change of FAT( Frenchay Arm Test) from baseline

    baseline, 1 month and 3 months post baseline

  • Change of FIM (Functional Independence Measure) from baseline

    baseline, 1 month, 3 months post baseline

  • Change of MMT( manual muscle testing) from baseline

    baseline, 1 month and 3 months post baseline

  • +5 more secondary outcomes

Study Arms (2)

Robot mediated Impairment-oriented training(RMIT)

EXPERIMENTAL

Participant receives 20 hours of robot mediated impairment-oriented training applied via the Optimo Regen

Device: Robot mediated upper limb therapy

Robot mediated impairment-oriented and task-specific training (RMIT+RMTT)

EXPERIMENTAL

Participant receives a total of 20 hours of robotic therapy. 10 hours will be in the form of RMIT and 10 hours in the form of RMTT

Device: Robot mediated upper limb therapy

Interventions

The OR is classified as a Class A device with the Health Sciences Authority. The OR is capable of delivering RMIT as well as RMTT. It can provide zero, partial or full assistance to the patient to complete the movement or task. Its teach-and-follow mode allows a movement to be performed by the therapist, with the device then "replaying" the movement at either zero, partial or full assistance for the patient. Impairment oriented training will focus on the following movements: 1. Diagonal movement 2. Shoulder abduction 3. Shoulder adduction 4. Shoulder flexion 5. Shoulder extension 6. Elbow flexion 7. Elbow extension Task-specific training will focus on the following activities: 1. Picking up a cup/glass by the side and drink 2. Brushing hair 3. Cleaning unaffected upper limb (hand to arm) 4. Wiping table 5. Wiping wall 6. Sliding card on table to a designated location 7. Clipping a clothe peg

Robot mediated Impairment-oriented training(RMIT)Robot mediated impairment-oriented and task-specific training (RMIT+RMTT)

Eligibility Criteria

Age21 Years - 99 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Diagnosis of stroke as evidenced by CT/MRI findings
  • First-ever stroke (ischaemic or haemorrhagic)
  • Upper limb weakness and an FMA-UE score of 16-53 (severe to moderate: 16-34. moderate to mild: 35-53)12,13
  • Cognitively intact to follow instructions
  • Medically stable to participate
  • Consent given
  • Age 21 and above

You may not qualify if:

  • \. Fractures or other musculoskeletal issues that render the use of the robotic device unsuitable 2. Involvement in another concurrent upper limb study 3. Wounds that do not allow donning of the device 4. Severe spasticity 5. Cognitive impairment (MMSE ≤20) 6. Inability to follow instructions 7. Severe osteoporosis 8. Infectious diseases that require the patient to be isolated in a single room eg airborne diseases

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Related Publications (3)

  • Conroy SS, Wittenberg GF, Krebs HI, Zhan M, Bever CT, Whitall J. Robot-Assisted Arm Training in Chronic Stroke: Addition of Transition-to-Task Practice. Neurorehabil Neural Repair. 2019 Sep;33(9):751-761. doi: 10.1177/1545968319862558. Epub 2019 Jul 22.

  • Mehrholz J, Pohl M, Platz T, Kugler J, Elsner B. Electromechanical and robot-assisted arm training for improving activities of daily living, arm function, and arm muscle strength after stroke. Cochrane Database Syst Rev. 2018 Sep 3;9(9):CD006876. doi: 10.1002/14651858.CD006876.pub5.

  • Hung CS, Hsieh YW, Wu CY, Lin KC, Lin JC, Yeh LM, Yin HP. Comparative Assessment of Two Robot-Assisted Therapies for the Upper Extremity in People With Chronic Stroke. Am J Occup Ther. 2019 Jan/Feb;73(1):7301205010p1-7301205010p9. doi: 10.5014/ajot.2019.022368.

MeSH Terms

Conditions

Stroke

Condition Hierarchy (Ancestors)

Cerebrovascular DisordersBrain DiseasesCentral Nervous System DiseasesNervous System DiseasesVascular DiseasesCardiovascular Diseases

Central Study Contacts

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
CARE PROVIDER, OUTCOMES ASSESSOR
Masking Details
To prevent subversion of the allocation sequence, study team members who enroll patients to the trial will be distinct and kept separate from the study team member that perform the randomization. We will establish the procedures to maintain separation between study team members that assess the outcomes, and those that perform group assignment. At the start of every assignment, patients will be reminded to not reveal their treatment assignment by referring to elements of the treatment that are unique to their treatment group. Functional outcome scales are performed by blinded therapists who work in the unit.
Purpose
TREATMENT
Intervention Model
PARALLEL
Model Details: Randomized controlled study
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

March 28, 2023

First Posted

April 10, 2023

Study Start

June 1, 2023

Primary Completion

May 31, 2025

Study Completion

December 31, 2025

Last Updated

April 10, 2023

Record last verified: 2023-03

Data Sharing

IPD Sharing
Will not share